U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
SEC File No:
NOTIFICATION OF LATE FILING 0-12968
Form 10-Q or 10-QSB
For Period Ended June 30, 1996
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
Not applicable. The filing relates to the
entire Form 10-Q or 10-QSB.
Part I--Registrant Information
Full Name of Registrant: INMEDICA DEVELOPMENT CORPORATION
Address of Principal Executive Office:
60 South 600 East, Suite 150
City, State and Zip Code: Salt Lake City, Utah 84102
Part II--Rules 12b-25(b) and (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if
appropriate)
[X] (a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable effort or
expense;
[X] (b) The subject annual report or semi-annual report/portion
thereof will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly
report/portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
<PAGE>
Part III--Narrative
State below in reasonable detail the reasons why Form 10-Q or
10-QSB or portion thereof could not be filed within the prescribed
time period.
The reason the report could not be timely filed is that
the Company's chief financial officer was out of town and
financial reporting questions arose after his departure
which affected the reports he had prepared and which
could not be resolved until his return.
Part IV--Other Information
(1) The person to contact in regard to this notification is:
Scott R. Jenkins (801) 531-8300
(2) Have all other periodic reports required under section 13
or 15(d) of the Securities Exchange Act of 1934 or section 30 of
the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file
such report(s) been filed? If the answer is no, identify
report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results
of operations from the corresponding period for the last fiscal
year will be reflected by the earnings statements to be included in
the subject report or portion thereof? [X] Yes [ ] No
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of results cannot be made.
The Company may report under its revenue recognition policy
certain as yet undetermined revenues for the quarter ended June 30,
1996 and is seeking to obtain the amount of such revenues during
the extension period. Recognized revenues are expected to be at
least $126,400. Gross revenues were $141,214 for the comparable
quarter of the prior year. The Company's general and
administrative expenses for the period covered by this report are
expected to be approximately the same as the prior period.
Research and development expenses are expected to be approximately
$65,000 for the current year quarter as compared to no research and
development expenditures during the comparable period of the prior
year. Net loss or income will depend upon the inclusion or
exclusion of additional royalty revenues referred to above.
<PAGE>
INMEDICA DEVELOPMENT CORPORATION
has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: August 13, 1996 By:/s/Larry E. Clark
Larry E. Clark, President
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The
name and title of the person signing the form shall be typed or
printed beneath the signature. If the statement is signed on
behalf of the registrant by an authorized representative (other
than an executive officer), evidence of the representative's
authority to sign on behalf of the registrant shall be filed with
the form.
<PAGE>
